Salvi Life Science Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 07-11-2024
- Paid Up Capital ₹ 0.10 M
as on 07-11-2024
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 1.18%
(FY 2023)
- Ebitda 1.93%
(FY 2023)
- Net Worth -40.64%
(FY 2023)
- Total Assets -0.98%
(FY 2023)
About Salvi Life Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kantilal Salvi, Nirav Salvi, and Kaushal Salvi serve as directors at the Company.
- CIN/LLPIN
U24290MH2020PLC352620
- Company No.
352620
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Salvi Life Science?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kantilal Salvi  | Director | 28-Dec-2020 | Current |
| Nirav Salvi | Director | 28-Dec-2020 | Current |
| Kaushal Salvi | Director | 28-Dec-2020 | Current |
Financial Performance and Corporate Structure Insights of Salvi Life Science.
Salvi Life Science Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 1.18% increase in profit. The company's net worth observed a substantial decline by a decrease of 40.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Salvi Life Science?
In 2023, Salvi Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Salvi Chemical Industries LimitedActive 19 years 2 monthsKantilal Salvi, Nirav Salvi and 1 more are mutual person
Nutracare Vitamin Private LimitedActive 1 year 9 monthsNirav Salvi and Kaushal Salvi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Salvi Life Science?
Salvi Life Science has a workforce of 0 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Salvi Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Salvi Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
